Atara Biotherapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
(In thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Additional · Other · Total | ||||||
| Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| For the Three Months Ended March 31, 2025 | Shares | Amount | Capital | Income (Loss) | Deficit | Equity (Deficit) |
| Balance as of January 1, 2025 | 5,859 | $1 | $1,957,261 | $8 | $(2,054,553) | $(97,283) |
| RSU settlements, net of shares withheld | 65 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 4,209 | — | — | 4,209 |
| Net (loss) income | — | — | — | — | 38,010 | 38,010 |
| Unrealized gain (loss) on available-for-sale securities | — | — | — | (8) | — | (8) |
| Balance as of March 31, 2025 | 5,924 | $1 | $1,961,470 | $— | $(2,016,543) | $(55,072) |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Additional · Other · Total | ||||||
| Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| For the Three Months Ended March 31, 2024 | Shares | Amount | Capital | Income (Loss) | Deficit | Equity (Deficit) |
| Balance as of January 1, 2024 | 4,258 | $— | $1,870,123 | $(204) | $(1,969,150) | $(99,231) |
| Issuance of pre-funded warrants to purchase common stock through a registered direct offering, net of offering costs of $177 | — | $— | $14,823 | $— | $— | $14,823 |
| Issuance of common stock through ATM facilities, net of commissions and offering costs of $168 | 493 | — | 9,312 | — | — | 9,312 |
| RSU settlements, net of shares withheld | 63 | — | (6) | — | — | (6) |
| Stock-based compensation expense | — | — | 8,397 | — | — | 8,397 |
| Net (loss) income | — | — | — | — | (31,752) | (31,752) |
| Unrealized gain (loss) on available-for-sale securities | — | — | — | 149 | — | 149 |
| Balance as of March 31, 2024 | 4,814 | $— | $1,902,649 | $(55) | $(2,000,902) | $(98,308) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.